GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (NAS:ATOS) » Definitions » E10

Atossa Therapeutics (Atossa Therapeutics) E10 : $-41.63 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Atossa Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Atossa Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.060. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-41.63 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Atossa Therapeutics was 13.60% per year. The lowest was 5.20% per year. And the median was 9.40% per year.

As of today (2024-04-30), Atossa Therapeutics's current stock price is $1.51. Atossa Therapeutics's E10 for the quarter that ended in Dec. 2023 was $-41.63. Atossa Therapeutics's Shiller PE Ratio of today is .


Atossa Therapeutics E10 Historical Data

The historical data trend for Atossa Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics E10 Chart

Atossa Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -65.53 -64.50 -61.56 -55.82 -41.63

Atossa Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.82 -53.51 -50.09 -45.33 -41.63

Competitive Comparison of Atossa Therapeutics's E10

For the Biotechnology subindustry, Atossa Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atossa Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Shiller PE Ratio falls into.



Atossa Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Atossa Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.06/129.4194*129.4194
=-0.060

Current CPI (Dec. 2023) = 129.4194.

Atossa Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -18.000 99.695 -23.367
201406 -23.400 100.560 -30.116
201409 -23.400 100.428 -30.155
201412 -43.200 99.070 -56.434
201503 -23.400 99.621 -30.399
201506 -19.800 100.684 -25.451
201509 -28.080 100.392 -36.199
201512 -24.360 99.792 -31.592
201603 -11.760 100.470 -15.148
201606 -8.040 101.688 -10.233
201609 0.840 101.861 1.067
201612 -8.640 101.863 -10.977
201703 -64.800 102.862 -81.530
201706 -7.720 103.349 -9.667
201709 -2.110 104.136 -2.622
201712 -0.752 104.011 -0.936
201803 -8.480 105.290 -10.423
201806 -5.080 106.317 -6.184
201809 -0.640 106.507 -0.778
201812 0.210 105.998 0.256
201903 -0.620 107.251 -0.748
201906 -0.800 108.070 -0.958
201909 -0.360 108.329 -0.430
201912 -0.260 108.420 -0.310
202003 -0.320 108.902 -0.380
202006 -0.430 108.767 -0.512
202009 -0.340 109.815 -0.401
202012 -0.880 109.897 -1.036
202103 -0.040 111.754 -0.046
202106 -0.060 114.631 -0.068
202109 -0.040 115.734 -0.045
202112 -0.040 117.630 -0.044
202203 -0.040 121.301 -0.043
202206 -0.053 125.017 -0.055
202209 -0.060 125.227 -0.062
202212 -0.060 125.222 -0.062
202303 -0.050 127.348 -0.051
202306 -0.080 128.729 -0.080
202309 -0.050 129.860 -0.050
202312 -0.060 129.419 -0.060

Add all the adjusted EPS together and divide 10 will get our e10.


Atossa Therapeutics  (NAS:ATOS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Atossa Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Atossa Therapeutics (Atossa Therapeutics) Business Description

Traded in Other Exchanges
Address
107 Spring Street, Seattle, WA, USA, 98104
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Executives
Gregory L Weaver director 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Heather Rees officer: SVP, Finance and Accounting C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET, SEATTLE WA 98104
Kyle Guse officer: CFO & General Counsel C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98102
H. Lawrence Remmel director C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
Shu-chih Chen director, 10 percent owner, officer: Chief Scientific Officer C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112
Steven C Quay director, 10 percent owner, officer: CEO 22026 20TH AVENUE S E, SUITE 102, BOTHELL WA 98021
Scott Youmans officer: Chief Operating Officer ATOSSA GENETICS INC., 2345 EASTLAKE AVE. E, SUITE 201, SEATTLE WA 98102
John E Sawyer officer: See Remarks C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98021
Christopher S. Destro officer: SVP, Sales and Marketing C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Peter J. Carbonaro officer: Sr. Vice President, Operations C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Ben R Chen officer: Sr. VP of Glob. Reg. Affairs 1616 EASTLAKE AVENUE EAST, SUITE 510, SEATTLE WA 98102
Richard I Steinhart director 125 ELM STREET, NEW CANAAN CT 06840
Alexander D Cross director C/O LIGAND PHARMACEUTICALS INC.,, 10275 SCIENCE CENTER DR., SAN DIEGO CA 92121
Stephen J Galli director C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
John Barnhart director C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112

Atossa Therapeutics (Atossa Therapeutics) Headlines

From GuruFocus